GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » 3-Year FCF Growth Rate

BioPharma Credit (LSE:BPCR) 3-Year FCF Growth Rate : 30.80% (As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit 3-Year FCF Growth Rate?

BioPharma Credit's Free Cash Flow per Share for the six months ended in Dec. 2022 was $0.12.

During the past 12 months, BioPharma Credit's average Free Cash Flow per Share Growth Rate was -30.40% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 30.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of BioPharma Credit was 30.80% per year. The lowest was 1.00% per year. And the median was 12.00% per year.


Competitive Comparison of BioPharma Credit's 3-Year FCF Growth Rate

For the Asset Management subindustry, BioPharma Credit's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioPharma Credit's 3-Year FCF Growth Rate Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, BioPharma Credit's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where BioPharma Credit's 3-Year FCF Growth Rate falls into.



BioPharma Credit 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


BioPharma Credit  (LSE:BPCR) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


BioPharma Credit 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


BioPharma Credit (LSE:BPCR) Business Description

Traded in Other Exchanges
N/A
Address
65 Gresham Street, 6th Floor, London, GBR, EC2V 7NQ
BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit (LSE:BPCR) Headlines

No Headlines